Previous 10 | Next 10 |
TARRYTOWN, N.Y., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has entered into an agreement with Regeneron to support clinical development, clinical manufacturing and t...
2023-08-22 08:14:05 ET Summary Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending positive phase 1 safety and pharmacokinetic data using APG777, the initiation of a 16-week phase 2 stud...
2023-08-21 15:58:31 ET More on Eli Lilly Eli Lilly Q2: Dividends Don't Lie Eli Lilly: Q2 And 2023 Revised Guidance Impressive, But Key Is Wegovy Data Eli Lilly and Co ( LLY ) Q2 2023 Earnings Call Transcript Eli Lilly Remains A Buy With Strong Sales And P...
2023-08-21 13:57:06 ET Summary On August 1, Merck released its financial report for the second quarter of 2023, which showed excellent results. Merck's revenue for the second quarter of 2023 was $15.04 billion, up 3.8% from the previous quarter and up 3.1% from the second quarter ...
2023-08-21 12:45:24 ET Regeneron Pharmaceuticals Inc (NASDAQ: REGN) secured FDA approval for Eylea HD – a higher-dose of its treatment for Macular Degeneration on Monday. Jim Cramer is bullish on Regeneron stock Shares of the biotech giant responded with an over 3.0% gain...
2023-08-21 06:30:00 ET Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence. The biotech has partnered with Bayer to create a dominant eye-disease franchise, led by Eylea (afl...
2023-08-19 14:00:56 ET More on Regeneron Pharmaceuticals Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rating Upgrade) Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening Regeneron Pharmaceuticals: Overdependence On Eylea Brought T...
2023-08-19 06:18:09 ET Summary Regeneron reported strong Q2 2023 financial results, with an 11% YoY revenue surge to $3.2B, outperforming expectations. The FDA approved high-dose Eylea (8 mg), offering less frequent treatment, addressing prior third-party filler concerns and bolst...
2023-08-18 21:10:28 ET More on Regeneron Regeneron could see share price bounce with potential approvals Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront Regeneron: Ey...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment approved in wAMD and DME for immediate do...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...